Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myelomonocytic, Acute 4Leukemia, Myeloid, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Lymphoma, Non-Hodgkin 3Wilms Tumor 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Melanoma 2Medulloblastoma 2Leukemia, Myelomonocytic, Chronic 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Ependymoma 2Congenital Abnormalities 2Breast Neoplasms 2Brain Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Xanthogranuloma, Juvenile 1

Interventions

Cancer Vaccines 2Adjuvants, Immunologic 2tipifarnib 1sagopilone 1Temozolomide 1Rituximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Central Nervous System Diseases × tipifarnib × Clear all
NCT00050986 2020-09-22

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

M.D. Anderson Cancer Center

Phase 1/2 Completed
55 enrolled 6 charts
CNS

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡